<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="discussion" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Adv. Drug. Alco. Res.</journal-id>
<journal-title>Advances in Drug and Alcohol Research</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Adv. Drug. Alco. Res.</abbrev-journal-title>
<issn pub-type="epub">2674-0001</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">10901</article-id>
<article-id pub-id-type="doi">10.3389/adar.2023.10901</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Health Archive</subject>
<subj-group>
<subject>Opinion</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Drug abuse results in metabolic and epigenetic changes in body which may contribute to disease risk: Role of L-carnitine and nutrients</article-title>
<alt-title alt-title-type="left-running-head">Virmani</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/adar.2023.10901">10.3389/adar.2023.10901</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Virmani</surname>
<given-names>Mohamed Ashraf</given-names>
</name>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1333562/overview"/>
</contrib>
</contrib-group>
<aff>
<institution>Medical and Scientific Affairs</institution>, <institution>Alfasigma BV</institution>, <addr-line>Utrecht</addr-line>, <country>Netherlands</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/26681/overview">Emmanuel Onaivi</ext-link>, William Paterson University, United States</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1233392/overview">Qing-Rong Liu</ext-link>, National Institute on Aging (NIH), United States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/278745/overview">Syed Ali</ext-link>, National Center for Toxicological Research (FDA), United States</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Mohamed Ashraf Virmani, <email>ashraf.virmani@alfasigma.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>18</day>
<month>01</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>3</volume>
<elocation-id>10901</elocation-id>
<history>
<date date-type="received">
<day>13</day>
<month>09</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>09</day>
<month>01</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Virmani.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Virmani</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<kwd-group>
<kwd>metabolic</kwd>
<kwd>epigenetic</kwd>
<kwd>co-factors</kwd>
<kwd>L-carnitine</kwd>
<kwd>micronutrients</kwd>
<kwd>mitochondria</kwd>
<kwd>dopamine</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction&#x2014;Drug abuse and health risk</title>
<p>Drug abuse is associated with significant health risk (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). Studies are also showing that there is an important connection between circadian rhythms, metabolism and addiction (<xref ref-type="bibr" rid="B3">3</xref>&#x2013;<xref ref-type="bibr" rid="B5">5</xref>). Study analyzing the liver metabolome of mice deficient in the expression of the dopamine D2 receptor (D2R) in striatal medium spiny neurons, found profound changes in the liver circadian metabolome compared to control mice (<xref ref-type="bibr" rid="B3">3</xref>). Further drugs that increase dopamine levels like cocaine disrupt circadian metabolic profiles in the liver. It is becoming evident that a strict communication exists between the CNS, and metabolism and this equilibrium can be altered by drug abuse (<xref ref-type="fig" rid="F1">Figure 1</xref>). This loss of equilibrium in drug abusers may increase risk of metabolic dysfunctions which may result in worsening addiction and possible disease states such as those manifested as the metabolic syndrome.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Drug abuse and the resulting diurnal, hormonal and metabolic/epigenetic changes in the body. Abbreviations: CNS, central nervous system; GH, growth hormone; T3, triiodothyronine; and T4, thyroxine.</p>
</caption>
<graphic xlink:href="adar-03-10901-g001.tif"/>
</fig>
</sec>
<sec id="s2">
<title>Drug abuse effects on metabolism and epigenetics</title>
<p>The metabolic syndrome is a collection of metabolic abnormalities, including hyperinsulinemia, hypertension, dyslipidaemia, and abdominal obesity, and may be triggered by initial discrepancies at the cellular level in critical metabolic pathways. These primary, small metabolic pathway disparities probably cascade with time leading in time to significant health problems. Some indications that drug abuse may increase the risk of the metabolic syndrome include the observation that drug-abusing patients have higher rates of diabetes complications. How drug abuse increases the risk to disease is being shown to be linked to changes in metabolism and epigenetics that are associated with the increased disease susceptibility. To counter these drug abuse related deleterious effects various studies, suggest that certain metabolic and antioxidant compounds like L-carnitine, thiamine (B1), co-enzyme Q10 etc., may be useful (<xref ref-type="bibr" rid="B6">6</xref>).</p>
<p>Drugs of abuse can be roughly categorised in different groups depending in part on their CNS activities, such as stimulants, amphetamines, hallucinogens, narcotics, inhalants, anaesthetics, anabolic steroids, and antipsychotics/antidepressants etc., (<xref ref-type="bibr" rid="B6">6</xref>). Each category and indeed each type of substance of abuse will affect metabolism differently depending on its unique chemical structure as well as the levels absorbed, processed and metabolised within the body. Furthermore, the effects on the metabolism within the body are manifested at various levels.<list list-type="simple">
<list-item>
<p>&#x2022; <bold>Cell functions</bold> such as neurotransmission, release of hormones and inflammatory factors (cytokines, extracellular vesicles).</p>
</list-item>
<list-item>
<p>&#x2022; <bold>Intra-cellular functions</bold> such as mitochondrial and endoplasmic reticulum (ER) activity.</p>
</list-item>
<list-item>
<p>&#x2022; <bold>Other body functions</bold> such as temperature, intestinal absorption of nutrients, intestinal biota, function of vascular system.</p>
</list-item>
</list>
</p>
<p>Therefore, each drug of abuse affects overall metabolism in a complex way and the metabolic changes can eventually contribute to damage to cells and organs that manifest as tissue damage and eventually to manifestation of increased ageing rate and diseases (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>). Thus, for example, excess alcohol consumption leads mitochondrial dysfunction and inhibited lipid metabolism and reduced insulin sensitivity, eventually causing alcoholic fatty liver disease (<xref ref-type="bibr" rid="B8">8</xref>).</p>
</sec>
<sec id="s3">
<title>Is it possible to protect against/reverse the metabolic and epigenetic changes due to drug abuse?</title>
<p>Every particular type of drug or substance of abuse has its own unique toxicity profile. Thus, amphetamines are known to affect the cardiovascular and neurological systems thereby exacerbating the risk factors for the metabolic syndrome. Methamphetamine users suffer cognitive deficits and abnormal metabolic activity, which affect nutritional status. The abuse of alcohol causes steatosis/liver injury as well as malnutrition leading to deficiencies in vitamin (B1, B2, B6, B12, C, K, A, and D) and minerals (selenium, zinc, magnesium, iron, and phosphorus) that significantly affect cellular metabolism as well as the epigenetic profile. The effects of these metabolic factors and their metabolites can impact gene expression by binding to transcription factors as well as by modifying chromatin structure and function (<xref ref-type="bibr" rid="B9">9</xref>&#x2013;<xref ref-type="bibr" rid="B12">12</xref>).</p>
<p>In the common and chronic alcohol use disorder (AUD) the multiple exposure to ethanol produces an overall reduced anxiety which may be linked to opening of chromatin by increased histone acetylation, increased cAMP-response element binding protein (CREB) levels, and histone deacetylase (HDAC) inhibition (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>). Acute ethanol exposure was found to increase H3 and H4 histone acetylation as well as increase CREB and CBP in the central nucleus of the amygdala and to decrease HDAC activity in the amygdala (<xref ref-type="bibr" rid="B13">13</xref>). Since many organ systems are affected by alcohol, a cross-tissue and cross-phenotypic analysis, showed a differentially methylated region in the proprotein convertase subtilisin/kexin 9 (PCSK9) gene (<xref ref-type="bibr" rid="B11">11</xref>). This PCSK9 hypomethylation was conserved across tissues and positively correlated with expression.</p>
<p>Similarly, in the heroin abuse disorder methylation levels of CpG sites HTR1B_07 and HTR1B_26 and the promoter region of the HTR1B gene were hypermethylated in heroin abusers compared to healthy controls (<xref ref-type="bibr" rid="B14">14</xref>).</p>
<p>The enzymes involved in epigenetic modifications of the DNA as well as the histone methylation/acetylation are reliant on specific micronutrient cofactors (<xref ref-type="fig" rid="F3">Figure 3</xref>) and their activity can be directly impacted by the levels of these cofactors like nicotinamide adenine dinucleotide (NAD), flavin adenine dinucleotide (FAD) as well as metabolic compounds like L-carnitine, Q10, etc. Chronic alcohol consumption has also been reported to leads to significant reductions in micronutrient especially thiamine and has been reported to contribute to DNA hypomethylation (<xref ref-type="fig" rid="F2">Figure 2</xref>). Thiamine deficiency in causes neurological injury leading to the Wernicke/Korsakoff syndrome (<xref ref-type="bibr" rid="B15">15</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Effects of alcohol on metabolism and gene regulation mechanisms [from Ref (<xref ref-type="bibr" rid="B7">7</xref>)]. The effects of ethanol are <italic>via</italic> effects on homocysteine/methionine metabolism as well as DNA methylation. Abbreviations: ATP, adenosine triphosphate; BHMT, betaine homocysteine methyltransferases; DNMTs, DNA methyltransferases; GSH, glutathione; HCC, hepatocellular carcinoma; MAT, methionine adenosyltransferase; MTHFR, methylene tetrahydrofolate reductase; 5-methyl THF, 5-methyl tetrahydrofolate; MS, methionine synthase; Pi, inorganic phosphate; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine.</p>
</caption>
<graphic xlink:href="adar-03-10901-g002.tif"/>
</fig>
</sec>
<sec id="s4">
<title>Future considerations</title>
<p>Studies are showing that drug abuse affects CNS as well as the diurnal rhythms of the whole body. These diurnal rhythm changes are also evident in at the level of cellular and organ metabolism (<xref ref-type="bibr" rid="B3">3</xref>). Drug abuse thus causes changes in gene expression and permanent epigenetic pattern changes which are related to the addiction and toxicity associated with long-term drug abuse. The metabolic and genetic/epigenetic dysfunctions over time in drug abuse may be countered or reduced by the use of micronutrients and metabolic cofactors, as well as by strategies utilising caloric restriction and preconditioning strategies. Exercise as well as environmental enrichment may be other strategies that impact on health of drug abusers (<xref ref-type="bibr" rid="B16">16</xref>). This may open ways to modulate the protective cellular pathways in a positive manner and reduce the impact of drug abuse.</p>
<p>Drug abuse related changes in metabolism would also have negative effects on various body systems due to increased cell damage, increased excitotoxicity, reduced energy production, and lowered antioxidant potential in cells. Partly this could also be due to mitochondrial dysfunction. This could be limited by adequate nutrient substrates and nutrient cofactors, especially L-carnitine, which play an important role in the mitochondrial function and metabolic flexibility (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Metabolism and Gene Regulation Mechanisms [From Ref (<xref ref-type="bibr" rid="B4">4</xref>)]. Abbreviations: ADP, adenosine diphosphate; ATP, adenosine triphosphate; CO<sub>2</sub>, carbon dioxide; H<sub>2</sub>O, water; NH<sub>3</sub>, ammonia; Ca<sup>2&#x2b;</sup>, calcium; e, electron; FAD, flavin adenine dinucleotide; NAD, nicotinamide adenine dinucleotide; ROS, reactive oxygen species.</p>
</caption>
<graphic xlink:href="adar-03-10901-g003.tif"/>
</fig>
<p>Energy from starting substrates such as glycogen, lipids, and proteins are gradually extracted by the complex series of enzymes in the cellular cytoplasm and mitochondria, resulting in metabolites, mainly CO<sub>2</sub> and H<sub>2</sub>O. Any dysfunction in this chain of events caused by lack of cofactors or mitochondrial dysfunction would lead to reduced ATP formation and increased ROS, Ca<sup>2&#x2b;</sup> and long chain fatty acid acyls and acylcarnitine buildup.</p>
<p>Further studies are needed to examine drug abuse related changes in gene/epigenetic expression and metabolism and to develop effective strategies to limit and reverse these changes. Indeed, certain metabolic compounds positively modulate the gene expression and associated protective cellular pathways and may contribute to limit drug abuse-related alterations and toxicity.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Author contributions</title>
<p>The author confirms being the sole contributor of this work and has approved it for publication.</p>
</sec>
<sec sec-type="COI-statement" id="s6">
<title>Conflict of interest</title>
<p>Author AV was employed by the company Alfasigma BV.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warner</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Buchsbaum</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>BE</given-names>
</name>
</person-group>. <article-title>Diabetic ketoacidosis associated with cocaine use</article-title>. <source>Arch Intern Med</source> (<year>1998</year>) <volume>158</volume>(<issue>16</issue>):<fpage>1799</fpage>&#x2013;<lpage>802</lpage>. <pub-id pub-id-type="doi">10.1001/archinte.158.16.1799</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Virmani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Binienda</surname>
<given-names>ZK</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Gaetani</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Metabolic syndrome in drug abuse</article-title>. <source>Ann N Y Acad Sci</source> (<year>2007</year>) <volume>1122</volume>:<fpage>50</fpage>&#x2013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1196/annals.1403.004</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cervantes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Della-Fazia</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Borrelli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sassone-Corsi</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Dopamine D2 receptor signaling in the brain modulates circadian liver metabolomic profiles</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2022</year>) <volume>119</volume>(<issue>11</issue>):<fpage>e2117113119</fpage>. <pub-id pub-id-type="doi">10.1073/pnas.2117113119</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Virmani</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Cirulli</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>The role of L-carnitine in mitochondria, prevention of metabolic inflexibility and disease initiation</article-title>. <source>Int J Mol Sci</source> (<year>2022</year>) <volume>23</volume>(<issue>5</issue>):<fpage>2717</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23052717</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henry</surname>
<given-names>JA</given-names>
</name>
</person-group>. <article-title>Metabolic consequences of drug misuse</article-title>. <source>Br J Anaesth</source> (<year>2000</year>) <volume>85</volume>(<issue>1</issue>):<fpage>136</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1093/bja/85.1.136</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Virmani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Binienda</surname>
<given-names>ZK</given-names>
</name>
</person-group>. <article-title>Neuroprotective strategies in drug abuse-evoked encephalopathy</article-title>. <source>Ann N Y Acad Sci</source> (<year>2010</year>) <volume>1199</volume>:<fpage>52</fpage>&#x2013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2009.05171.x</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bachi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sierra</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Volkow</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>RZ</given-names>
</name>
<name>
<surname>Alia-Klein</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Is biological aging accelerated in drug addiction?</article-title> <source>Curr Opin Behav Sci</source> (<year>2017</year>) <volume>13</volume>:<fpage>34</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.cobeha.2016.09.007</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamas-Paz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>V&#xe1;zquez</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Canals</surname>
<given-names>S</given-names>
</name>
<name>
<surname>G&#xf3;mez Del Moral</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Alcoholic liver disease: Utility of animal models</article-title>. <source>World J Gastroenterol</source> (<year>2018</year>) <volume>24</volume>(<issue>45</issue>):<fpage>5063</fpage>&#x2013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v24.i45.5063</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zakhari</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Alcohol metabolism and epigenetics changes</article-title>. <source>Alcohol Res</source> (<year>2013</year>) <volume>35</volume>(<issue>1</issue>):<fpage>6</fpage>&#x2013;<lpage>16</lpage>.</citation>
</ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cadet</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Jayanthi</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Epigenetics of addiction</article-title>. <source>Neurochem Int</source> (<year>2021</year>) <volume>147</volume>:<fpage>105069</fpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2021.105069</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lohoff</surname>
<given-names>FW</given-names>
</name>
<name>
<surname>Sorcher</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Mauro</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Fanelli</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Momenan</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Methylomic profiling and replication implicates deregulation of PCSK9 in alcohol use disorder</article-title>. <source>Mol Psychiatry</source> (<year>2018</year>) <volume>23</volume>(<issue>9</issue>):<fpage>1900</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2017.168</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bohnsack</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Pandey</surname>
<given-names>SC</given-names>
</name>
</person-group>. <article-title>Histone modifications, DNA methylation, and the epigenetic code of alcohol use disorder</article-title>. <source>Int Rev Neurobiol</source> (<year>2021</year>) <volume>156</volume>:<fpage>1</fpage>&#x2013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/bs.irn.2020.08.005</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandey</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Ugale</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Prakash</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Brain chromatin remodeling: A novel mechanism of alcoholism</article-title>. <source>J Neurosci</source> (<year>2008</year>) <volume>28</volume>:<fpage>3729</fpage>&#x2013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5731-07.2008</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dang</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group> <article-title>Methylation and expression quantitative trait locus rs6296 in the HTR1B gene is associated with susceptibility to opioid use disorder</article-title>. <source>Psychopharmacology (Berl)</source> (<year>2022</year>) <volume>239</volume>(<issue>8</issue>):<fpage>2515</fpage>&#x2013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-022-06141-5</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leevy</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Moroianu</surname>
<given-names>SA</given-names>
</name>
</person-group>. <article-title>Nutritional aspects of alcoholic liver disease</article-title>. <source>Clin Liver Dis</source> (<year>2005</year>) <volume>9</volume>:<fpage>67</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.cld.2004.11.003</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Madeo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hempel</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group> <article-title>A red nucleus-VTA glutamate pathway underlies exercise reward and the therapeutic effect of exercise on cocaine use</article-title>. <source>Sci Adv</source> (<year>2022</year>) <volume>8</volume>(<issue>35</issue>):<fpage>eabo1440</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.abo1440</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>